"Successful automation depends on orchestration, not just robotics," notes Werner Maas, PhD, CEO, Hudson Lab Automation.

This is what the finished product of a blog on WordPress will look like. Each title and image represents a new “post.” What does a Blog on WordPress look like? Should I use one on my site? You can use ...

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...

Latus Bio Inc. has reported IND clearance by the FDA for LTS-101, a gene therapy candidate to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease. The ...

LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore ...

An interactive, comprehensive training platform designed to teach Git and GitHub fundamentals to developers of all skill levels. This tutorial covers all essential version control and collaboration ...

Welcome to Winged Canvas, your Online School of Illustration and Art Nerd Community! 🌟 We're not just a YouTube channel; we're a collective of passionate artists and educators on a mission to make ...

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

The MarketWatch News Department was not involved in the creation of this content. In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved ...

Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy ...

Syntis Bio, a startup aiming to bring patients a key benefit of gastric bypass surgery but in the form of a pill, has raised $33 million as its lead program continues early clinical development as a ...